



Material Safety Data Sheet

Product Name: Recombinant adeno-associated virus (rAAV)
Concentration: 1E11 to 1E12 genome copy (GC) per ml
Formulation: Phosphate buffer saline (PBS), pH 7.4
with 0.001% Pluronic F-68
Producer contact: Applied Viromics, LLC
4160 Technology Dr. Suite D3
Fremont, CA 94538
Tel: (510) 266-2646 Fax: (510) 440-8044

For research use only. CAUTION: Not intended for human or animal diagnostic or therapeutic uses.

1. PRODUCT CHARACTERISTICS

AAV is a non-envelop DNA virus of 20-25 nm in diameter, with a single stranded DNA genome of 5000 bases, and protein capsids that differ between various serotypes (1 to 8). Replication of AAV is dependent on co-infection of helper viruses such as adenovirus or herpesvirus. AAV is capable of infecting non-dividing cells and form stable integration into the host cell genome.

2. HAZARD INFORMATION

Pathogenicity: No known pathology for wild type AAV serotype 2, which is found in 40% of human population. No sufficient data are available for the pathogenicity of other AAV serotypes in healthy human subject.

Source of infection: exposure to laboratory cultures of recombinant virus via ingestion/inhalation, droplet exposure of the mucous membrane, or direct injection; contact with feces or urine from infected animals within 72 hours post infection.

Survival outside of host: can be several weeks under normal environmental conditions.

3. LABORATORY HANDLING AND PRECAUTIONS

Containment Requirements: Biosafety level 2 containment facilities for all activities involving the virus, recombinant virus vectors, and potentially infectious body fluids or tissues.

Protective Clothing: Laboratory coat, gloves, safety glasses/goggles.

Decontamination: Susceptible to 5% phenol, 10% bleach, or 10% Wescodyne. Recommend fresh solution of 10% bleach for 30 minutes.

Spills: Allow aerosols to settle 15 minutes; wear protective clothing and gently cover the spill with adsorbent paper towel and apply freshly prepared 10% bleach starting at the perimeter and working towards the center; allow at least 30 minutes contact time before clean up.

Disposal: Decontaminate all wastes before disposal by incineration or by steam sterilization for 60 minutes. Follow instruction in your institution in terms of labeling, containment, and transportation of decontaminated waste.

Storage: In containers that are tightly closed, appropriately labeled, and in approved locations for BSL 2 materials at -70°C .

Transport: Material must be sealed in primary and secondary containers, appropriately labeled.

4. FIRST AID/MEDICAL INFORMATION

Anti-viral agent: No specific anti-viral drug available. No immunization or prophylaxis measures available.

First Aid/Treatment: For splashes to the eye of virus-containing material, rinse eye at eyewash for 15 minutes then report to hospital emergency room for evaluation. In the case of accidental injection of material containing virus, wash area well with soap and water then contact office of Occupational Health for advice and evaluation. Notify supervisor and EH&S as soon as possible after incidence of exposure.

5. PRECAUTIONS RELATED WITH OTHER GENETIC MATERIAL

AAV vectors generated at Applied Viromics are recombinant and lack any AAV viral protein coding sequences or helper viruses. However, rAAV genome replication can occur if the infected subject has been pre-infected with wtAAV. Unforeseen risk exists due to the potentially hazardous nature of transgenes inserted in AAV genome, together with any other foreign elements that are introduced which could alter the specificity, host range, stability, or infectivity of the resulting vector.

It is imperative that investigators use caution in handling recombinant AAV vectors and consider both the nature of the virus used as a vector and the effects of any transgene, introduced genetic elements, or other modifications.

We will not be hold responsible for the accuracy, sufficiency, or reliability of this information or for any loss or injury resulting from the use of this information.